Format

Send to

Choose Destination
Ann Surg Treat Res. 2019 Apr;96(4):185-190. doi: 10.4174/astr.2019.96.4.185. Epub 2019 Mar 28.

Actual compliance to adjuvant chemotherapy in gastric cancer.

Author information

1
Department of Surgery, Dankook University Hospital, Cheonan, Korea.
2
Gastric Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Korea.
3
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
4
Department of Surgery, Keimyung Univsity School of Medicine, Daegu, Korea.
5
Department of Surgery, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
6
Department of Surgery, Ajou University School of Medicine, Suwon, Korea.
7
Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea.
8
Department of Surgery, Bucheon St. Mary's Hospital, Bucheon, Korea.
9
Department of Surgery, Korea Cancer Center Hospital, Seoul, Korea.
10
Department of Surgery, Konyang University Hospital, Daejeon, Korea.
11
Department of Surgery, Korea University College of Medicine, Seoul, Korea.
12
Department of Surgery, Incheon St. Mary's Hospital, Incheon, Korea.
13
Department of Surgery, Jeju National University Hospital, Jeju, Korea.

Abstract

Purpose:

This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer.

Methods:

From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea.

Results:

We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (≥60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354); by body mass index (BMI) (≥23 kg/m2 vs. <23 kg/m2) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively.

Conclusion:

The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m2, and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.

KEYWORDS:

Adjuvant chemotherapy; Advanced gastric cancer; Compliance

Conflict of interest statement

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

Supplemental Content

Full text links

Icon for The Korean Surgical Society Icon for PubMed Central
Loading ...
Support Center